Organogenesis Inc.

Bio-active wound healing, biosurgery and cosmeceuticals and cosmetic surgery

Organogenesis (AMEX - ORG) was founded in 1986. It was the first company to receive an FDA approval for a living human cell based product.

Geoff MacKay, President & CEO
Gary S. Gillheeney, Sr., Executive VP, COO and CFO
Vincent Ronfard, CSO

150 Dan Road
Canton, Massachusetts 02021
USA
Phone: +1-781-575-0775

Organogenesis’ product portfolio focuses on the development of living tissue replacements, organ assist treatments and guided tissue regeneration scaffolds. Organogenesis is a leader in tissue engineering; its Apligraf® living skin construct is the flagship of the company. Apligraf is supplied as a bi-layered cell therapy, consisting of living cells and structural proteins. Unlike human skin, though, Apligraf does not contain melanocytes, Langerhans’ cells, macrophages, and lymphocytes, or any other structures such as hair follicles, blood vessels or sweat glands. Detailed information on this therapy is provided at www.apligraf.com. Novartis Pharma AG has global marketing rights of Apligraf ®. FortaPerm™ , FortaGen™ and PuraPly™ have recently achieved marketing clearance. CuffPatch™ serves as a one-time usable and resorbable collagen based implant to reinforce soft tissue. This product is distributed by the Arthrotek sports medicine division of Biomet Inc. The Organogenesis research pipeline also includes the Vitrix™ living dermal replacement, a coronary vascular graft and a liver assist device and Testskin™ II, a living skin device that mimics the actual skin properties for in vitro testing. Revitix™ is a topical cosmeceutical preparation that is being developed for the rejuvenation of skin consisting of human skin growth factors.

The company also has a comprehensive patent portfolio; some of the most important patents are listed below.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.